|
PharmaVoice 2016: “Industry experts discuss the potential of precision medicine and the impact this will have on R&D and commercial operations. Click here to read more.
These 17 women are transforming the healthcare industry with technologies designed to enhance efficiency, quality and access of care.
Kate Torchilin, PhD, MBA. Novaseek Research. Novaseek Research seeks to transform how researchers access human biospecimens and clinical data to drive research and development. Dr. Torchilin founded the company with the vision of accelerating research and enhancing precision medicine via the cloud platform, Clinical Data Network for Research. Various New England hospitals have implemented the Novaseek platform. Before taking on the role of CEO at Novaseek Research, Dr. Torchilin served as CEO of Biocell Center as well as in management positions at Connected Health, Alere and Thermo Fisher Scientific. She also worked at Beth Israel Deaconess Medical Center and Harvard Medical School teaching hospital. Dr. Torchilin earned her master's degree in business administration from Harvard Business School in Boston and her doctorate in biochemistry from Tufts University in Medford, Mass. Click here to read more. Most patients in the United States are treated in community hospitals and physician practices, a trend that could grow under the Affordable Care Act. By contrast, most life sciences research in the United States takes place at academic institutions, not at smaller hospitals. But community hospitals can do more to support research and give patients an opportunity to participate.
Conducting research can enable hospitals to offer cutting-edge treatments to their patients and to build a reputation for innovation that attracts forward-thinking clinicians. Hospitals known for their research often attract more patients who want to incorporate the latest medical thought and the most effective therapies into their care. Participating in research enhances a hospital’s image as a local center of excellence. It can also attract federal and industry funding. Precision Medicine Initiative In the past several years, the Federal Drug Administration and the National Institutes of Health have recognized the importance of broader patient engagement in the community health care setting for various research studies. The Precision Medicine Initiative announced by the White House in January 2015, in fact, counts on community hospital participation. Funded for the first time in fiscal 2016, it hinges on the recruitment and follow-up of 1 million or more people throughout the United States who will allow their medical data and biospecimen and lifestyle information to be collected and used for research. This massive cohort will be followed to gain insights into a range of important health care questions. Data from such a broad segment of society will help researchers correlate genomics and environmental factors with disease onsets and progression and determine the most effective options to prevent disease and improve outcomes. A key requirement of the PMI is to “ensure that people historically underrepresented in biomedical research are included in sufficient numbers to allow robust inferences in these groups.” Often, this means involving patients in community hospitals. Barriers to Participation Many health care organizations, however, struggle to balance research engagement with their core mission of providing patient care. Nonacademic medical centers face a number of roadblocks, including concerns about increasing staff workloads, disrupting work practices and research ethics. Additionally, participation in research requires an understanding of research regulations, including requirements of the FDA, the Office for Human Research Protections and the Health Insurance Portability and Accountability Act. Community hospitals can easily overcome many of these barriers by ensuring that research activities adhere as closely as possible to existing hospital workflows, thus minimizing any deviations from standard practices for hospital personnel and patients. In addition, hospitals can now apply various information technology approaches to their electronic health records systems. A Different Way to Participate Community hospitals can get involved in life sciences research at both the discovery and the clinical stages. While most hospitals think of research activities as clinical trials, in the era of precision medicine and the drive toward improved outcomes, there are many other ways hospitals can give their patients a chance to contribute to medical advances. For example, collecting biological specimens (such as blood, urine, tissue and saliva) with associated data is a valuable contribution to many research studies. The life sciences industry, academic institutions and the federal government, particularly the National Institutes of Health, have all invested heavily in biospecimen resources through federal grants and contracts involving both academic medical centers and community hospitals. For example, the Collaborative Human Tissue Network, funded by the National Cancer Institute, had more than 100 hospitals over the course of 20-plus years provide specimens to thousands of researchers. Contributing institutions have included academic medical centers like the University of Pennsylvania and Vanderbilt as well as smaller community hospitals. In another example, the Massachusetts Hospital Association has partnered with a local startup to use new technologies to bridge the gap between community hospitals and academic and private researchers, thereby accelerating work that advances precision medicine. In this case, hospitals automatically collect data from the electronic health records of consenting patients and ensure that specimen collection corresponds with existing hospital practices. Patient Interest Patients, especially those with a personal interest in medical advances, increasingly are asking how they can contribute to research. Many community hospitals now participate in research efforts based on requests from their patients. But privacy and patient consent remain fundamental. Patients should have the ability to participate or to decline. National data show that a large majority of patients participate in research when presented with the opportunity, and they typically report a positive experience — especially if they can take part in an efficient, minimally intrusive manner. With the move toward personalized medicine, many hospitals need to be prepared for future research and patient care needs. Community hospitals are in a position to enable more patients to choose to participate in research, even if they are not being treated at a major academic research center. The ultimate goal is to establish and nurture collaboration between patients, hospitals and life sciences researchers to foster rapid improvements in care. Written by Kate Torchilin, Ph.D., MBA Published in Hospitals & Health Networks Magazine By KATE TORCHILIN, PHD
We live in a golden age of medicine. Never before have so many effective treatment options been available to so many people. And precision medicine is bringing new horizons, as well as the promise to further improve disease prevention, treatment, and ultimately find more cures. To keep moving toward personalized medicine approaches, more individuals would need to participate in research studies. Fortunately, people are often willing to engage in life sciences research when informed of the opportunity and its importance. At its best, research is a socially beneficial endeavor that empowers individuals to contribute to the betterment of health at large. However, life sciences research isn’t as efficient as it could be. Many projects fail in the early stages, and it takes too long to progress new molecules from discovery to clinical trials. Improving the current state of life sciences research will require collaborative efforts on the parts of several stakeholders — in particular, hospitals, patients, and researchers. What the Stakeholders Can Do Hospitals are important arenas for research, as they treat an enormous number of individuals each year — nearly 35 million in 2014 in the U.S. alone. Further, they obtain biospecimens and associated clinical data as part of their normal operations, and both would be beneficial for researchers if sharing them were streamlined. However, effective participation of hospitals in research does not always happen because the first priority of physicians and hospitals is tending to patients’ needs; additional pursuits like research aren’t always feasible. Therefore, research activity — especially involving basic life sciences — has largely been limited to major academic hospitals with the funding to dedicate staff to research. Unfortunately, given the complex natures of many diseases (like cancer and the need to study chronic conditions like diabetes and rheumatoid arthritis at the population level), it has become harder to identify enough patients for studies within academic medical centers’ walls. This ultimately slows down research and also limits the ability of healthcare providers to improve patient outcomes. Where there is inefficiency, there is opportunity. By forming creative collaborations, most hospitals can become important contributors to life science research while continuing to embrace a patient-centric approach. Hospitals are of course already set up in a patient-centric way: Teams of healthcare providers work to identify and treat problems on an individual basis. However, the information gleaned from patients is typically compartmentalized and unavailable to researchers. A crucial step in hospital engagement comes from educating hospital personnel about research opportunities so that they may, in turn, educate patients. But the first step is to understand patients’ priorities. Patients typically want to support research, but they can’t be expected to dedicate enough time for it. Therefore, the easier it is for them to participate, the more likely they are to do so. For example, approaches that track and collect biospecimens and associated data from patients when they come in to see their doctors and other healthcare providers would be a good start. It is important to keep complete transparency toward patients about research opportunities and to respect their privacy and choices by implementing proper patient consenting approaches. The research field has been moving toward opt-in patient consent as the best practice (e.g., patients have to expressly give their consent to participate in research projects). Patients are much more interested in research after learning about the opportunities and what such involvement entails. More resources are becoming available for hospitals, even in the community setting, that are willing to get involved with research, such as grants from the Precision Medicine Initiative for the creation of a large-scale research participation cohort and grants for quality, effectiveness, and accessibility research. The biggest factor enabling patient research contribution through hospital participation is the digitization of health records that has occurred in the U.S. over the last decade. Whereas paper documents require extensive work to organize and share, electronic medical charts and health records can be screened automatically in order to identify patients who might qualify for research projects, as well as track patients who have consented to participation in various projects. In addition to expediting the process, there is also reduced potential for human error in the data collection process, as well as higher data security standards. Also, researchers often need biospecimens such as urine or blood samples. For consenting patients, blood samples may be collected with the existing workflow as part of routine annual checks or other routine patient visits to hospitals when samples are already being sent to the lab. Fitting research into existing workflow reduces burden on both the hospital staff and the patient by limiting the number of trips they take for involvement in research projects. Understanding the priorities of life sciences researchers is another area where we can improve. They often have specific questions that they need to answer, and they have to operate within the constraints of certain budgets and timelines. Any solution for improved efficiency of and insights from the variety of research projects has to be easy to use, provide the right information at the right time, and fit their budgets. An aligned, high-tech, efficient life sciences research setup would be a powerful tool that could enable collaboration among patients, healthcare providers, and researchers. The concept is a win-win arrangement that would hasten the advancement of medicine. Through novel utilization strategies of electronic records and existing hospital workflows, research can now be easily accommodated by the hospitals and should result in greater patient engagement. In the long run, it will pay off in the form of improved healthcare outcomes. This post appears through the MedCity News MedCitizens program. Community hospitals can begin to take on increased roles in clinical research and, in doing so, significantly expand the patient population that can access various studies. Click here to read more.
New Clinical Data Network Technologies Improve Access to Patients
New technology is enabling biopharma researchers to reach groups of patients that traditionally have been hard to reach. Over 80% of all patients in the U.S. are treated in community healthcare settings, so these institutions hold the key to facilitating research with populations that are ethnically, racially, geographically, and socio-economically diverse. Federal agencies, including the FDA and NIH, have taken steps to encourage or mandate increased diversity in research and broader patient engagement in community healthcare settings. On the industry side, R&D organizations are increasingly focused and interested in approaches that result in the right treatment for the right patient at the right time. Key to realizing such outcomes are broader population-based studies that further the understanding of “multi-omic” diversity and how that diversity influences healthcare outcomes. An engaged society with millions of individuals’ biologic information available to researchers will enable faster progress in medical developments. Today, accessing such information is achievable. The widespread use of electronic medical records (EMRs) combined with improved data analytics can help researchers find and access patients, whether in large metropolitan hospitals, community hospitals, or other healthcare organizations that traditionally had limited research participation. Furthermore, the application of new technologies and methodologies can now automate the necessary collection of both clinical information and biospecimens from the right patient populations either directly or during a visit to a doctor. This approach creates a virtual, sustainable, and more efficient ecosystem on which to base precision medicine research. Published by Kate Torchilin, PhD in Genetic Engineering and Biotechnology News The efficient translation of discovery projects to clinical trials is necessary to improve productivity, decrease the risk of R&D projects, and ultimately deliver better medicines to patients faster.
Clinical and discovery groups in pharmaceutical and biotechnology companies are increasingly working together to share insights about the potential clinical impact of biomedical discoveries much earlier in the process. Biomarkers are an essential part of such a translational effort and are critical to understanding human disease. Human biospecimens can provide a bridge between the early discovery and molecular mechanism of the disease and the clinical utility. Commonly, human biospecimens are used to:
In the discovery phase of a project, it’s important to use biospecimens that accurately reflect the phenotype of patients who will be involved in clinical trials later. For example, if they’re studying potential markers or drug responses for a disease that has several different subtypes, researchers should acquire specimens from patients with that specific subtype of the disease. Or if the trial revolves around certain responses in patients who exhibit early stages of a disease, the biospecimens should be taken from patients in those early stages. There are typically three main areas that need to be considered when planning biospecimen collections: the characteristics of the biospecimen (biological), the characteristics of the patient (clinical), and the budget and timeline required (operational). Unfortunately, it can be difficult for researchers in discovery and preclinical areas to apply a comprehensive understanding of patient clinical data, even when trying to find the right biospecimens. Additionally, budgets and timelines are often hard to predict at the beginning of a project. Unlike an online search engine, however, there’s usually no single source of information to find out whether available specimens meet the exact criteria. Therefore, the procurement can be a slow, manual process of calls and emails between researchers and vendors trying to identify what kinds of biospecimens might be available. It can take days, weeks, or even months to obtain the necessary samples, depending on the specific requirements. Further complications arise when information gets lost in translation. A vendor may not ask for particulars, such as the necessary subtype of the disease in question, and the researcher might not know to specify. Such details, if ignored, can impact the biological significance of the discoveries made with the use of biospecimens, resulting in failure during the validation, translational, or clinical phases. The risks can be mitigated when researchers have clear, comprehensive clinical information, in addition to biological information, as early as the discovery and preclinical phases. When researchers have reliable, transparent data on the biospecimens early on and can choose those that most accurately reflect the types of patients who will be enrolled in the clinical trial, the risks of failure are substantially reduced. Here are four areas to consider to accurately plan projects that require human biospecimens:
Published by Kate Torchilin Ph.D. in Pharma iQ Boston, MA, February 17, 2016 – Novaseek Research today announced that it is a winner of the inaugural 2015 Pistoia Alliance President’s Startup Challenge.
The Pistoia Alliance is a global, not-for-profit alliance of life science companies, vendors, publishers, and academic groups that work together to lower barriers to innovation in R&D. The Startup Challenge 2015 panel of expert judges, drawn from the Pistoia Alliance’s membership, evaluated more than 30 start-up companies from around the world who are developing new ideas to lower the barriers to innovation in life sciences R&D. Dr. Kate Torchilin, CEO of Novaseek Research said: “Novaseek is honored to receive this award. Going through the rigorous process of judging and working with our mentor at Pistoia allowed us to substantially enhance our Clinical Data Network for Research (CDNR) platform, the industry’s first comprehensive platform for accessing clinical data and human biospecimens that are essential for understanding diseases and developing medical advances.” Novaseek’s CDNR platform enables biomedical researchers to realize the power of the electronic medical record (EMR), opening access to clinical data from consenting patients and thousands of biospecimens flowing through hospital laboratories each day. CNDR features powerful real-time analytics for project planning and timing of biospecimen fulfillment. It also enables researchers to specify criteria such as lab values, gender, diagnosis and medication history, and then match these search criteria to biospecimens in the hospitals. Novaseek and its healthcare partners use IRB-approved protocols and patient consents to ensure the ethical conduct of research and respect for all participants. About the Pistoia Alliance The Pistoia Alliance is a global, not-for-profit alliance of life science companies, vendors, publishers, and academic groups that work together to lower barriers to innovation in R&D. Our projects transform R&D innovation through pre-competitive collaboration. We bring together the key constituents to identify the root causes that lead to R&D inefficiencies. We develop best practices and technology pilots to overcome common obstacles. Our members collaborate as equals on open projects that generate significant value for the worldwide life sciences community. For further information about the Pistoia Alliance please visit our website: http://www.pistoiaalliance.org/ About the Pistoia Alliance President’s Startup Challenge 2015 The Pistoia Alliance Startup Challenge is a global competition for small to medium enterprises developing new technologies and services that will benefit the life sciences industry. Entries must support the Pistoia Alliance’s mission to lower barriers to innovation in life sciences R&D. The finalists and winners will each receive a cash prize along with mentorship from industry experts drawn from the Pistoia Alliance’s membership. More information is available at: http://www.pistoiaalliance.org/startup2015 About Novaseek Novaseek is transforming how biomedical researchers access clinical data and human biospecimens to accelerate R&D. The Novaseek Clinical Data Network for Research (CDNR) is the industry’s first comprehensive platform enabling researchers to access real-world, real-time clinical data and large quantities of high quality biospecimens – that is essential for understanding disease and developing medical advances – all in compliance with HIPAA. Incorporating Novaseek’s CDNR platform across all phases of research and development helps industry and academia generate powerful new insights, increases R&D productivity and decreases risk in the pursuit of new cures. The CDNR platform was developed by experts in drug development, hospital operations and health IT to create a win-win for industry, academia, healthcare providers and patients. Boston, MA, January 7, 2016 – Massachusetts Hospital Association (MHA) and Novaseek Research today announced a novel collaboration that will enable Massachusetts-based hospitals and patients to contribute broadly to the advancement of biomedical research. Through this collaboration, MHA member hospitals will leverage Novaseek’s state-of-the art platform to provide researchers in industry and academia with biospecimens and associated clinical data from consenting patients, accelerating research into the diagnosis and treatment of human disease.
Breakthroughs in medicine require the support of patients and healthcare organizations of all sizes. However, many institutions struggle to balance research engagement with their core mission of providing patient care. The Novaseek platform makes contributing to biomedical research easier than ever before by plugging into health information systems at hospitals and labs, and matching data and specimens from consenting patients directly to research needs. Getting access to clinical data and biospecimens is a chronic problem that continues to delay or derail vital research projects. Novaseek integrates clinical data from multiple healthcare organizations, ensuring that the data is HIPAA-compliant and easy to use in R&D. Novaseek’s platform realizes the potential of the electronic medical record (EMR) by accessing streams of data on thousands of specimens from consenting patients that flow through hospital laboratories each day and that would otherwise be discarded. It provides researchers with powerful analytics, based on real-world real-time data, and supports project planning and biospecimen accrual projections. Furthermore, the platform enables researchers to specify criteria such as lab values, gender, diagnosis and medication history, and then match these search criteria to biospecimens in the hospitals. Novaseek and its healthcare partners use IRB-approved protocols and patient consents to ensure the ethical conduct of research and respect for all participants. “We are excited to collaborate with the Massachusetts Hospital Association,” said Dr. Kate Torchilin, CEO, Novaseek Research. “Novaseek was born from the need to bridge the world of life sciences research and the hospital world. Our collaboration with MHA is also strategically aligned with the objectives of the NIH’s Precision Medicine Initiative announced earlier this year.“ “Novaseek Research is a key technology leader who will enable more patients at more hospitals to participate in vital biomedical research,” said Lynn Nicholas, President and CEO of MHA. “As the first hospitals in Massachusetts begin to adopt Novaseek’s platform, we are proud to promote getting consented patient data and samples into the hands of researchers who are developing new treatments and cures , and further strengthening Massachusetts’ preeminent position in life sciences research.” About MHA The Massachusetts Hospital Association (MHA) is a voluntary, not-for-profit organization comprised of hospitals and health systems, related organizations, and other members with a common interest in promoting the good health of the people of the Commonwealth. Through leadership in public advocacy, education, and information, MHA represents and advocates for the collective interests of its members and supports their efforts to provide high quality, cost effective and accessible care. While Massachusetts hospitals and other care providers are facing an era of unprecedented change, MHA members remain committed to their most basic mission: caring for people. To continue to fulfill this mission, the hospitals and health systems of Massachusetts support a set of fundamental values. We believe that the health care system must:
About Novaseek Novaseek connects researchers from industry and academia with healthcare organizations, and enables broad patient participation in medical advances. The Novaseek Clinical Data Network for Research (CDNR) is the industry’s first HIPAA compliant comprehensive platform that enables researchers to access real-world, real-time clinical data and large quantities of high quality biospecimens. Incorporating Novaseek’s CDNR platform across all phases of research and development helps to generate powerful new insights, increases R&D productivity, and decrease risk in the pursuit of new cures. The CDNR platform was developed by experts in drug development, hospital operations and health IT to create a win-win for industry, academia, healthcare providers and patients. Cambridge, MA – January 4, 2016 – Novaseek Research announced today that the Company has been selected to deliver a corporate presentation at the first annual Digital Health Showcase, a focused program within the Biotech Showcase investor and networking conference, concurrent with JP Morgan Healthcare annual conference. The upcoming event is being held in San Francisco, CA at Parc 55. Biotech Showcase event is expected to bring together 2,100+ attendees representing the life science industry’s most enterprising and pioneering biotech companies and major players in the drug development arena.
Dr. Kate Torchilin, CEO at Novaseek Research, will be presenting on Wednesday, January 13, 2016 at 9:20 AM PT. Dr. Torchilin will provide a corporate overview of how Novaseek connects life sciences R&D with healthcare providers via proprietary IP platform, and enables broad patient participation in medical advances. Novaseek’s first offering is transforming how researchers from industry and academia access clinical data and human biospecimens to accelerate R&D. About Novaseek Novaseek connects researchers from industry and academia with healthcare providers, and enables broad patient participation in medical advances. The Novaseek Clinical Data Network for Research (CDNR) is the industry’s first comprehensive platform enabling researchers to access real-world, real-time clinical data and large quantities of high quality biospecimens – that is essential for understanding disease and developing medical advances – all in compliance with HIPAA. Incorporating Novaseek’s CDNR platform across all phases of research and development helps industry and academia generate powerful new insights, increases R&D productivity and decreases risk in the pursuit of new cures. The CDNR platform was developed by experts in drug development, hospital operations and health IT to create a win-win for industry, academia, healthcare providers and patients.  Pistoia Start Up Challenge Finalists 2015. Kate Torchlin, CEO, Novaseek 3rd from right. Boston, MA, October 14, 2015 – Novaseek Research, an innovator in clinical data and biospecimens for research, today announced that it was selected as a finalist for the prestigious Pistoia Alliance President’s Startup Challenge 2015. Novaseek provides life science industry and academia with access to real-world real-time human biospecimens and associated clinical data in compliance with HIPAA.
The Pistoia Alliance is a global, not-for-profit alliance of life science companies, vendors, publishers, and academic groups that work together to lower barriers to innovation in R&D. The Startup Challenge 2015 panel of expert judges, drawn from the Pistoia Alliance’s membership, evaluated more than 30 start-up companies from around the world who are developing new ideas to lower the barriers to innovation in life sciences R&D. “We are thrilled to be a selected as a finalist of this prestigious award for our innovative approach to providing access to clinical data and human biospecimens to R&D organizations,” said Kate Torchilin, CEO, Novaseek Research. “We will further utilize the award and collaboration with Pistoia Alliance to solve a major industry bottleneck of sourcing clinically annotated tissue specimens, in addition to biofluids. Also, via our Clinical Data Network for Research (CDNR) platform, we will greatly increase the number of hospitals participating in biospecimen collections.“ Today, industry and academia need access to clinical data and biospecimens to accelerate discovery and translational studies. However, identifying the right patient at the right time, and getting access to biospecimens and data, has been a chronic problem that continues to delay or derail vital research and development projects. Novaseek’s CDNR platform resolves these problems by enabling researchers to efficiently and effectively incorporate clinical data and biospecimens into their discovery programs. The CDNR platform is currently available to early adopters in industry, academia and government. Preferential CDNR license terms are offered until the end of year 2015. Requests should be send to: info@novaseekresearch.com About Novaseek Novaseek is transforming how biomedical researchers access clinical data and human biospecimens to accelerate R&D. The Novaseek Clinical Data Network for Research (CDNR) is the industry’s first comprehensive platform enabling researchers to access real-world, real-time clinical data and large quantities of high quality biospecimens – that is essential for understanding disease and developing medical advances – all in compliance with HIPAA. Incorporating Novaseek’s CDNR platform across all phases of research and development helps industry and academia generate powerful new insights, increases R&D productivity and decreases risk in the pursuit of new cures. The CDNR platform was developed by experts in drug development, hospital operations and health IT to create a win-win for industry, academia, healthcare providers and patients. Boston, MA, October 1, 2015 – Novaseek Research today unveiled the Clinical Data Network for Research (CDNR) platform, the industry’s first comprehensive platform providing researchers in the life science industry and academia with access to real-world real-time clinical patient data and human biospecimens in compliance with HIPAA.
Access to data and biospecimens is essential to understanding diseases and developing novel therapies, especially in the era of precision medicine. Using Novaseek’s CDNR platform across all phases of discovery and development will help researchers to generate powerful new insights, increase R&D productivity and decrease project risk in the pursuit of new cures. “Today, more than ever before, industry and academia need access to clinical data and biospecimens to accelerate discovery and translational studies. However, identifying the right patient at the right time and getting access to data and biospecimens is a chronic problem that continues to delay, or worse, derail vital research and development projects,” said Dr. Kate Torchilin, CEO, Novaseek Research. “Novaseek’s CDNR platform resolves these problems by enabling researchers to incorporate patient data and specimens into their discovery programs.” The Novaseek CDNR platform enables researchers to access:
Dr. Torchilin added, “The Novaseek CDNR makes it easy for hospitals and other healthcare provider organizations to support research in industry, academia, and government, without deviation from hospital workflows. The platform identifies consented cases that match complex clinical criteria, allowing laboratory staff to intercept samples and provide them for research. Importantly, all data and specimens are provided in compliance with HIPAA.” The CDNR platform is currently available to early adopters in industry, academia and government. Preferential CDNR license terms are offered until the end of year 2015. Requests should be send to: info@novaseekresearch.com About Novaseek Novaseek is transforming how biomedical researchers access clinical data and human biospecimens to accelerate R&D. The Novaseek Clinical Data Network for Research (CDNR) is the industry’s first comprehensive platform enabling researchers to access real-world, real-time clinical data and large quantities of high quality biospecimens – that is essential for understanding disease and developing medical advances – all in compliance with HIPAA. Incorporating Novaseek’s CDNR platform across all phases of research and development helps industry and academia generate powerful new insights, increases R&D productivity and decreases risk in the pursuit of new cures. The CDNR platform was developed by experts in drug development, hospital operations and health IT to create a win-win for industry, academia, healthcare providers and patients. |
